Picture

Matinas BioPharma @MatinasBio

Matinas BioPharma ( $MTNB ) is focused on improving the intracellular delivery of nucleic acids and small molecules with its LNC platform technology. matinasbiopharma.com Bedminster, NJ Joined June 2014
  • Tweets
    2K
  • Followers
    10K
  • Following
    2K
  • Likes
    10
MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

Successful in vivo LNC platform studies support the future use of the LNC platform in inflammation and oncology. For LNC platform updates, please visit: bit.ly/4cC1tGc $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

$MTNB CEO comments on the clear registration pathway & FDA agreement on the ORALTO Ph. 3 trial for MAT2203, and MAT2203's potential to represent a new treatment paradigm for the treatment of a variety of difficult to treat #invasivefungalinfections. bit.ly/4cC1tGc

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

To participate in today's conference call at 4:30 p.m. ET (1:30 p.m. PT), please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll), or access a live audio webcast here: bit.ly/3IStBHz $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

Matinas reports 2023 financial results and provides a business update. The Company will host a conference call and webcast today beginning at 4:30 p.m. ET (1:30 p.m. PT). For dial-in and webcast details, please visit: bit.ly/4cC1tGc $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

The positive in vivo safety data with Matinas' oral LNC-docetaxel formulation build on data from a prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel. For study design & key takeaways, please visit: bit.ly/3TQF4O3 $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

Matinas will report 2023 financial results after market close on March 27th. Matinas management will host an investment community conference call & webcast to discuss financial results & provide a business update that day at 4:30pm ET (1:30pm PT). bit.ly/3IStBHz $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

4 weeks ago

In an in vivo study, daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss (toxicity), compared to an average peak weight loss of 20% with IV-docetaxel. For key takeaways: bit.ly/3TQF4O3 $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

a month ago

"MAT2203 continues to demonstrate its potential to effectively treat invasive #fungalinfections & help patients achieve complete clinical resolution," said $MTNB CEO. Learn about the complete clinical response in 3 patients following treatment with MAT2203 bit.ly/4cFQrjx

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

a month ago

Dr. Theresa Matkovits, Chief Development Officer at Matinas comments on the complete clinical response in three patients with invasive fusarium infection following treatment with MAT2203. Learn more: bit.ly/4cFQrjx $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

2 months ago

“MAT2203 may be particularly promising for the treatment of #invasivefungalinfections in patients with limited options and therefore satisfy a currently significant unmet medical need,” said Dr. Miceli. Learn about the Expanded Access Program with MAT2203: bit.ly/3IcyAT3

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

2 months ago

Dr. Theresa Matkovits, Chief Development Officer at Matinas comments on the potential of MAT2203 in treating a broad spectrum of deadly #invasivefungalinfections. For more info: bit.ly/3IcyAT3 $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

2 months ago

Matinas today provided a positive outcomes update from its ongoing Compassionate/Expanded Use Access Program with its oral #antifungal MAT2203, including multiple patients with complete clinical resolution. For details: bit.ly/3IcyAT3 $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

2 months ago

Our CEO Jerome D. Jabbour comments on successfully reaching agreement with FDA and Matinas' plans to advance MAT2203 into a single Phase 3 registration trial for the treatment of invasive aspergillosis. Learn about the ORALTO trial: bit.ly/3uEDwNr $MTNB

MatinasBio Profile Picture

Matinas BioPharma @MatinasBio

2 months ago

Dr. Theresa Matkovits, Chief Development Officer at Matinas comments on achieving alignment with the FDA on the design of a single Phase 3 trial to support the registration of MAT2203 for the treatment of invasive aspergillosis. For more information: bit.ly/3uEDwNr $MTNB

Trends for United States

Chelsea
440 B posts
$QUACK
8.870 posts
Poch
54,3 B posts
#NotcoinGame
Havertz
121 B posts
#COYG
10,4 B posts
#ARSvsCFC
11,5 B posts
$TSLA
37 B posts
Ben White
22,4 B posts
Odegaard
33,3 B posts
Cole Palmer
36,6 B posts
#Xbox97Sweepstakes
38,4 B posts
Enzo
42,6 B posts
#Arsenal
15,1 B posts
The FTC
18 B posts
Martinelli
13,4 B posts
Pecker
131 B posts
National Enquirer
25,3 B posts
Badiashile
18,4 B posts
Mervis
1.184 posts

You might like

#Chatspin is a random cam to cam site where you can instantly #connect with #strangers. Thousands of users online at all times. https://t.co/5CNsOd6FMX
Chatspin
@chatspin
26K Followers
iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression.
iTolerance
@iTolerance_inc
3K Followers
@SADA's podcast for business leaders and technology enthusiasts exploring how @GoogleCloud is transforming the industry. Check it out: https://t.co/blgjbQaUyW
Cloud N Clear
@cloudnclear
8K Followers
We are a clinical-stage pharmaceutical company focused on improving the outcomes and lives of cancer patients.
Panavance
@panavance
2K Followers
Setting the new standard in #payroll #benefits and #HR for small businesses & the accountants who love them.
OnPay
@onpay_payroll
22K Followers
Moleculin (NASDAQ: $MBRX) is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant cancers and viruses.
Moleculin Biotech
@moleculinbio
5K Followers
Rooted in science. Obsessed with quality. We put the health of your family first.
ViaCord
@ViaCord
12K Followers
For more than 45 years, Associa has brought positive impact and meaningful value to communities. To learn more, visit https://t.co/deuYRcUUld.
Associa
@Associa
11K Followers
Archer Financial Services shows dedication to our clients through integrity, financial stability, market knowledge & execution services | 1-877-690-7303
AFS
@TradeWithAFS
7K Followers
At TheSaleMark, you will find the latest #Sales trend, Sales strategies, and Cutting-edge solutions to achieve your sales goal.
TheSalesMark
@TheSalesMark
3K Followers
We are an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders.
AIM ImmunoTech
@AimImmuno
4K Followers
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. $FBIO
Fortress Biotech
@fortressbio
16K Followers
Global payments industry leader, providing clarity to the complex through analytics + intelligence. Supporting payments pros with news/insights via NewsFilter.
TSG
@tsgpayments
10K Followers
GoLinks transforms ugly, long URLs into human-readable go links. Creator of https://t.co/6QHbE8H1p1 & https://t.co/hjxRlE18d7. Try everything free ⬇️
GoLinks
@GoLinks
9K Followers
MTIG is dedicated to enhancing the regulatory, investment, and commercial environment to accelerate microbiome therapeutic drug product development.
MTIG
@MTIG_News
4K Followers